Biochemical superglue opens new approach to vaccine development

March 31, 2017, University of Oxford
Credit: University of Oxford

An Oxford University spinout company is developing a molecular superglue for the rapid development of vaccines targeting a range of diseases.

SpyBiotech is using 'biochemical superglue' that can facilitate the rapid development of robust and novel vaccines. The company has raised £4m at launch in seed financing to develop the technology, led by Oxford Sciences Innovation with participation from GV.

The company gets its name from the bacterium Streptococcus pyogenes (Spy), the same organism behind a number of infections including strep throat and impetigo. The team behind SpyBiotech divided Spy into a peptide, SpyTag, and a protein partner, SpyCatcher. Naturally attracted to each other, the two form a covalent bond once combined.

SpyBiotech believes that this bond is the missing link to effective development and production of highly effective vaccines. The company will initially focus on virus-like particles (VLPs), a leading technology to induce immune responses by vaccination. Discovered in 1963, VLPs have become a cornerstone of a number of vaccines. Resembling viruses but without pathogenic material, VLPs can instead be coated with bug-busting antigens. However, the two most common ways in which a VLP can be paired with antigens – genetic fusion and chemical conjugation – are imprecise, expensive, prone to being misassembled, and consequently can result in the failure of a vaccine.

Conversely, SpyBiotech's SpyVLP can be easily and efficiently combined with a number of antigens, and used to produce stable vaccines that induce robust antibody responses. The company plans to target infectious diseases including major viral infections at first, with a view to developing SpyVLP into a universal platform that can be adapted to target a wide variety of conditions. In particular, owing to the versatile and easy-to-use nature of SpyVLP, the technology could underpin efforts to rapidly combat future outbreaks and pandemics.

SpyBiotech will use the seed funding to get its first candidates ready for Phase I trials. During that period, SpyBiotech's founders will receive support from its investors. The founders are aiming to start a further round of funding in the near future to catalyse the development of SpyVLP and expand into other disease areas. A leadership team, including the company's first CEO, will be announced in the coming months.

Sumi Biswas, Associate Professor at the Jenner Institute, Oxford University, said: 'Researchers in the vaccine field, including us, have struggled to make effective VLPs against many diseases for a long time. We view this superglue technology as a game changer to enable faster development of effective vaccines against major global diseases. We are excited to begin the journey of taking this versatile and innovative approach forward and moving our new vaccines from the laboratory to human clinical testing.'

Oxford Sciences Innovation (OSI), the patient capital investor for Oxford University, led the £4m investment, with GV (formerly Google Ventures), an independent venture capital arm of Alphabet, joining in participation.

Lachlan MacKinnon, Principal at OSI, said: 'We see the Spy technology as the missing link in rapid and robust VLP and see GV as a natural co-investment partner to take this forward. We are privileged to be working with four founders who bring such an impressive combination of academic prowess and clinical stage experience to the company.'

Tom Hulme, General Partner at GV, added: 'SpyBiotech has established a novel approach using platform VLP vaccine technology that shows promise in a number of addressable markets. We're looking forward to working with a team of world class scientists with extensive experience in vaccine development – spanning from design through to Phase II clinical trials – to develop more effective vaccines for a wide range of global diseases.'

The research underpinning SpyBiotech was developed in conjunction between researchers at Oxford University's Department of Biochemistry and Jenner Institute, with four academics joining SpyBiotech at launch. The team includes: Mark Howarth, Professor of Protein Nanotechnology; Sumi Biswas, Associate Professor of Vaccinology; Simon Draper, Professor of Vaccinology; and Dr. Jing Jin. Combined, the founding team has taken twelve products to Phase I and II trials; filed nine patents on vaccines and other technologies; and has extensive experience in biotech and industrial collaborations and partnerships. The commercialisation of SpyBiotech's technology and company formation is supported by Oxford University Innovation, the research commercialisation company of Oxford University.

Carolyn Porter, Deputy Head of Technology Transfer at Oxford University Innovation, said: 'SpyBiotech punctuates research that's been developing for some time here at Oxford, and is a testament to the benefits of collaboration between our departments and institutes. Oxford is playing a leading role in developing the next generation of vaccines, and SpyBiotech – and other spinouts working in this sector – showcases the potential impact the University can have on the wider world.'

Explore further: Synthetic biologists use bacterial superglue for faster vaccine development

Related Stories

Experts seek to jump-start vaccine development

February 23, 2017

Although many infectious diseases lack vaccines, current vaccine research is limited, primarily due to an understandable but unfortunate lack of commercial interest. A new article identifies and discusses the gaps in human ...

Recommended for you

Engineers repurpose wasp venom as an antibiotic drug

December 7, 2018

The venom of insects such as wasps and bees is full of compounds that can kill bacteria. Unfortunately, many of these compounds are also toxic for humans, making it impossible to use them as antibiotic drugs.

Researchers probe hydrogen bonds using new technique

December 7, 2018

Researchers at Carnegie Mellon University have used nuclear resonance vibrational spectroscopy to probe the hydrogen bonds that modulate the chemical reactivity of enzymes, catalysts and biomimetic complexes. The technique ...

Are amorphous solids elastic or plastic?

December 7, 2018

In a crystalline solid, the atoms form an ordered lattice. Crystalline solids respond elastically to small deformations: When the applied strain is removed, the macroscopic stress, as well as the microscopic configuration ...

Molecular insights into spider silk

December 7, 2018

Spider silk is one of the toughest fibres in nature and has astounding properties. Scientists from the University of Würzburg discovered new molecular details of self-assembly of a spider silk fibre protein.

Copycat cells command new powers of communication

December 7, 2018

From kryptonite for Superman to plant toxins for poison ivy, chemical reactions within the body's cells can be transformative. And, when it comes to transmuting cells, UC San Diego researchers are becoming superhero-like ...


Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 31, 2017
I am not even a little bit of a conspiracist but what happened to what I consider -"The Holy Grail" of vaccine development breakthru talked about here?
Did it get suppressed/hidden because it would eliminate so many other drugs and money?
This was a way of making a vaccine not the vaccine itself, so it should work on any animal not just mice.
key words 100% effective against Virus, bacteria, parasite.
not rated yet Mar 31, 2017
Ok no conspiracy to cover it up. MIT is, working on/has made, a zika vaccine using their system.
not rated yet Apr 02, 2017
Holy Shit!

Yet this was not even mentioned as a major breakthrough in 2016?
As a side note I read somewhere that the gates foundation had invested millions and millions of dollars in a project to develop vaccines fast to fight a future plague. But it was kind of secretive about where the money went. Do you suppose???

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.